A

    Armata Pharmaceuticals Inc (ARMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $5.51
    +0.14 (+2.61%)

    Market Cap: $199.67M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    -18.61%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.57
    Range$-0.57 - $-0.57
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.53+7.0%
    60d ago$-0.39+31.6%
    30d ago$-0.39+31.6%
    7d ago$-0.39+31.6%
    Current$-0.57
    Revenue Consensus
    $900000
    Range$900000 - $900000
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.88
    Range$-0.88 - $-0.88
    1 analysts
    Revenue Consensus
    $4M
    Range$4M - $4M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.88---
    Sep 26EST
    		-$-0.57---
    Jun 26
    		$-0.27$-0.48+43.75%Beat+6.9%
    Mar 26
    		$-3.16$-0.38-731.58%Miss-1480.0%
    Dec 25
    		$-0.51$-0.19-169.05%Miss-120.6%
    Sep 25
    		$-0.33$-0.42+21.43%Beat-120.0%
    Jun 25
    		$-0.29$-0.39+25.64%Beat+27.5%
    Mar 25
    		$-0.20$-0.38+47.37%Beat+39.4%
    Dec 24
    		$-0.23$-0.35+33.80%Beat+57.9%
    Sep 24
    		$-0.15$-0.28+46.43%Beat+53.1%
    Jun 24
    		$-0.40$-0.36-11.11%Miss-48.1%
    Mar 24
    		$-0.33$-0.31-6.45%Miss-6.5%
    Dec 23
    		$-0.55$-0.35-57.14%Miss-89.7%
    Sep 23
    		$-0.32$-0.31-3.23%Miss-33.3%
    Jun 23
    		$-0.27$-0.37+27.03%Beat-3.8%
    Mar 23
    		$-0.31$-0.32+3.13%Beat-3.3%
    Dec 22
    		$-0.29$-0.28-3.57%Miss-26.1%
    Sep 22
    		$-0.24$-0.28+14.29%Beat+4.0%
    Jun 22
    		$-0.26$-0.23-13.04%Miss-4.0%
    Mar 22
    		$-0.30$-0.21-42.86%Miss-11.1%
    Dec 21
    		$-0.23$-0.28+17.86%Beat+36.1%
    Sep 21
    		$-0.25$-0.26+3.85%Beat+19.4%
    Jun 21
    		$-0.25$-0.26+3.85%Beat+3.8%
    Mar 21
    		$-0.27$-0.32+15.63%Beat+44.9%
    Dec 20
    		$-0.36$-0.29-24.14%Miss+25.0%
    Sep 20
    		$-0.31$-0.25-24.00%Miss+57.5%
    Jun 20
    		$-0.26$-0.35+25.71%Beat+53.6%
    Mar 20
    		$-0.49$-0.31-58.06%Miss+68.2%
    Dec 19
    		$-0.48$-0.72+33.33%Beat+77.1%
    Sep 19
    		$-0.73$-0.45-62.22%Miss+47.9%
    Jun 19
    		$-0.56$-0.36-55.56%Miss+78.9%
    Mar 19
    		$-1.54$-1.54+0.00%Beat+54.2%
    Dec 18
    		$-2.10$-0.98-114.29%Miss+40.0%
    Sep 18
    		$-1.40$-1.40+0.00%Beat-11.1%
    Jun 18
    		$-2.66$-2.80+5.00%Beat-119.8%
    Mar 18
    		$-3.36$-2.66-26.32%Miss+87.6%
    Dec 17
    		$-3.50$-5.04+30.56%Beat-933.3%
    Sep 17
    		$-1.26N/A+79.07%Beat+97.2%
    Jun 17
    		$-1.21N/AN/ABeat-
    Mar 17
    		$-27.16N/A+76.34%Beat-
    Dec 16
    		$0.42N/A+101.00%Beat-
    Sep 16
    		$-44.80$-57.40+21.95%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.29EV/EBITDA14.44x
    Price/FCF-7.85xFCF Yield-12.74%
    Profitability
    Profit Margin0.00%Operating Margin-410.80%
    ROE-3439.00%ROIC601.39%
    Financial Health
    Debt/Equity-0.89xInterest CoverageN/A
    Current Ratio0.11xQuick Ratio0.11x
    Trading Statistics
    Beta1.33Avg Volume115.32K
    52-Week High$14.9852-Week Low$2.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.16
    SMA 20$4.87
    SMA 50$5.13
    SMA 200$7.53
    EMA 10$5.22
    EMA 20$5.06
    EMA 50$5.47
    EMA 200$6.47

    MACD

    Line: 0.10Signal: -0.04Hist: 0.13

    ADX

    ADX: 14.4+DI: 19.6-DI: 20.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down48.0
    PSAR$4.42

    Bollinger Bands

    Upper Band$5.72
    Lower Band$4.03
    %B Position3477%(Upper)
    Band Width0.88

    RSI (14-Day)

    Neutral
    56.8

    Momentum Oscillators

    Stoch %K84.9
    Stoch %D85.3
    Williams %R-10.9
    ROC (10d)23.0%
    Momentum1.03
    CCI (20d)119.9
    MFI (14d)45.9

    Volatility Measures

    ATR (14d)$0.53(9.6%)
    StdDev (20d)0.42
    Hist Vol108.2%(High)

    Volume Flow

    VWAP$5.40
    OBV24.8M
    AD Line1.5M
    CMF (20d)0.086

    Volume Metrics

    Avg Vol (20d)118.1K
    Vol Ratio0.4x(Low)
    VWMA (20d)$4.82

    Pivot Points

    R3$6.01
    R2$5.73
    R1$5.55
    Pivot Point$5.27
    S1$5.09
    S2$4.81
    S3$4.63

    Advanced Oscillators

    TSI4.93
    Ultimate Osc76.4
    KST63.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.51M$789,000$1.08M$1.16M$2.17M$491,000$1.24M$2.97M$0$966,000$1.53M$1.23M
    Cost of Revenue$0$0$418,000$0$0$0$380,000$0$0$0$293,000$0
    Gross Profit$2.51M$789,000$1.08M$1.16M$2.17M$491,000$1.24M$2.97M$0$966,000$1.53M$1.23M
    Operating Expenses$12.82M$9.57M$14.91M$8.94M$9.01M$8.68M$11.77M$12.73M$11.91M$11.19M$11.11M$11.56M
    R&D$7.59M$6.11M$6.07M$5.82M$6.39M$5.43M$8.45M$9.48M$8.47M$8.02M$7.93M$7.98M
    SG&A$5.24M$3.46M$3.43M$3.11M$2.62M$3.25M$3.32M$3.24M$3.44M$3.18M$3.18M$3.58M
    Operating Income$-10,312,000$-8,785,000$-13,823,000$-7,776,000$-6,844,000$-8,191,000$-10,538,000$-9,756,000$-11,914,000$-10,228,000$-9,579,000$-10,336,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$106.56M$110.47M$0$9.45M$0$-2,166,000$0$0$0$10.27M$3.86M
    Income Before Tax$74.14M$-115,346,000$-124,298,000$-26,675,000$-16,295,000$-6,531,000$2.60M$-5,481,000$8.99M$-25,021,000$-19,847,000$-31,161,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$74.14M$-115,346,000$-124,298,000$-26,675,000$-16,295,000$-6,531,000$2.60M$-5,481,000$8.99M$-25,021,000$-19,847,000$-31,161,000
    EBITDA$74.73M$-114,889,000$-123,880,000$-26,305,000$-15,929,000$-6,154,000$814,000$-5,168,000$9.30M$-24,704,000$-19,490,000$-27,077,000
    EBIT$74.14M$-115,346,000$-124,298,000$-26,675,000$-16,295,000$-6,531,000$434,000$-5,481,000$8.99M$-25,021,000$-19,783,000$-27,298,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARMP

    News

    Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP

    Madison Asset Management LLC has acquired a new position in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP), purchasing over 2.1 million shares valued at approximately $13.65 million, giving it a 5.74% stake in the company. Other institutional investors like BlackRock Inc. also initiated or increased their holdings, though overall institutional ownership remains low at 3.57%. Despite the stock opening at $5.07, well below its 52-week high, analysts maintain a "Moderate Buy" consensus with an average price target of $15, supported by the company's focus on developing bacteriophage therapies for antibiotic-resistant infections.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP

    Armata Pharmaceuticals, Inc. (AMEX:ARMP) generated $4.90 million USD in revenue last year, primarily from its Pathogen-specific Bacteriophage Therapeutics segment. This marks a decrease from the $5.17 million USD reported in the previous year. The revenue largely originated from the United States and Australia.

    TradingView•8/14/26•
    Neutral

    Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS

    Armata Pharmaceuticals (ARMP) reported its quarterly earnings, exceeding analyst expectations with an adjusted loss of $0.27 per share against an anticipated loss of $0.48. The company's revenue also significantly surpassed estimates, reaching $2.51 million compared to a consensus of $0.40 million. Following these results, shares rose 1.4% to $4.31, and the company maintains a "Moderate Buy" consensus rating from analysts with a $15 average price target.

    MarketBeat•8/12/26•
    Somewhat-Bullish

    Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary

    Armata Pharmaceuticals, Inc. reported significantly improved financial results for the 2026 quarter, with revenue reaching $2.51M and net income soaring to $74.14M, a substantial increase from a net loss in the prior year. The diluted loss per share also narrowed. The company highlighted positive Phase 2 clinical results for two of its drug candidates, progress in regulatory agreements with the FDA, and expanded grant support, though it noted the need for additional financing to sustain its clinical programs.

    TradingView•8/12/26•
    Bullish

    Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP)

    This article provides an overview of Armata Pharmaceuticals, Inc. (AMEX:ARMP) stock performance, financial estimates, and key metrics. It includes information on current stock price, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports. The content also addresses frequently asked questions regarding the company's stock.

    TradingView•8/1/26•
    Somewhat-Bearish

    Frequently Asked Questions About ARMP

    Does ARMP pay dividends?
    Armata Pharmaceuticals Inc (ARMP) does not currently pay a regular dividend.
    What is ARMP's market cap?
    Armata Pharmaceuticals Inc (ARMP) has a market capitalization of $199.67M with a current stock price of $5.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In